Top

Published in:

01-03-2019 | Laser | Review Article

Laser capture microdissection: techniques and applications in liver diseases

Authors: Beatriz Aguilar-Bravo, Pau Sancho-Bru

Published in: Hepatology International | Issue 2/2019

Abstract

Routine transcriptomic and proteomic analysis are usually performed at a whole organ or tissue level. These approaches provide an average readout of all cell types present within the tissue but do not allow differentiating the profile of specific cell populations. Laser capture microdissection (LCM) constitutes an excellent tool to isolate cell populations or areas of interest within a tissue. By direct visualization, the selected area is excised by a laser and can be further processed for a variety of downstream analyses. This technology has been widely used in the study of liver diseases, from DNA and RNA sequencing to mass spectrometry. However, LCM also has important limitations. To ensure the best integrity of the molecule of interest, optimal tissue preservation, careful tissue sectioning, and optimization of the staining procedure are required. The present review provides a description of the LCM technology, including tips and technical recommendations to perform the procedure, as well as an overview of studies using LCM technology in the field of liver disease.

Kandathil AJ, Graw F, Quinn J, Hwang HS, Torbenson M, Perelson AS, et al. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 2013;145(1404–1413):e10

Henriet E, Abou Hammoud A, Dupuy J-W, Dartigues B, Ezzoukry Z, Dugot-Senant N, et al. Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk. Hepatology 2017;66:2016–2028CrossRefPubMed

Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science 1996;274:998–1001CrossRefPubMed

Fodor SP, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. DNA SEQUENCING: massively parallel genomics. Science (80-) [Internet] 1997;277:393–395 (American Association for the Advancement of Science) CrossRef

Murray GI, Curran S. Laser capture microdissection: methods and protocols. New York: Humana Press; 2005.CrossRef

Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture microdissection. Nat Protoc 2006;1:586–603CrossRefPubMed

Fang J, Schneider B. Laser microdissection: a sample preparation technique for plant micrometabolic profiling. Phytochem Anal 2014;25:307–313CrossRefPubMed

Datta S, Malhotra L, Dickerson R, Chaffee S, Sen CK, Roy S. Laser capture microdissection: big data from small samples. Histol Histopathol 2015;30:1255–1269PubMedPubMedCentral

Liu H, Mcdowell TL, Hanson NE, Tang X, Fujimoto J, Rodriguez-Canales J. Laser capture microdissection for the investigative pathologist. Vet Pathol 2014;51(1):257–269CrossRefPubMed

10.

Tangrea MA, Mukherjee S, Gao B, Markey SP, Du Q, Armani M, et al. Effect of immunohistochemistry on molecular analysis of tissue samples: implications for microdissection technologies. J Histochem Cytochem 2011;59:591–600(in press 10.1002/HEP.30472)CrossRefPubMedPubMedCentral

11.

Liu A. Laser capture microdissection in the tissue biorepository. J Biomol Tech 2010;21:120–125 (The Association of Biomolecular Resource Facilities) PubMedPubMedCentral

12.

Vandewoestyne M, Goossens K, Burvenich C, Van Soom A, Peelman L, Deforce D. Laser capture microdissection: should an ultraviolet or infrared laser be used? Anal Biochem 2013;439:88–98CrossRefPubMed

13.

Gallagher RI, Blakely SR, Liotta LA, Espina V. Laser capture microdissection: ArcturusXT infrared capture and UV cutting methods. New York: Humana Press; 2012. pp. 157–178

14.

Yi L, Liang Z-T, Peng Y, Yao X, Chen H-B, Zhao Z-Z. Tissue-specific metabolite profiling of alkaloids in Sinomenii Caulis using laser microdissection and liquid chromatography–quadrupole/time of flight-mass spectrometry. J Chromatogr A 2012;1248:93–103 (Elsevier) CrossRefPubMed

15.

Schad M, Mungur R, Fiehn O, Kehr J. Metabolic profiling of laser microdissected vascular bundles of Arabidopsis thaliana. Plant Methods 2005;1:2 (BioMed Central) CrossRefPubMedPubMedCentral

16.

Dilillo M, Pellegrini D, Ait-Belkacem R, de Graaf EL, Caleo M, McDonnell LA. Mass spectrometry imaging, laser capture microdissection, and LC-MS/MS of the same tissue section. J Proteome Res 2017;16:2993–3001CrossRefPubMed

17.

Hutchinson RW, Cox AG, McLeod CW, Marshall PS, Harper A, Dawson EL, et al. Imaging and spatial distribution of β-amyloid peptide and metal ions in Alzheimer’s plaques by laser ablation—inductively coupled plasma—mass spectrometry. Anal Biochem 2005;346:225–233CrossRefPubMed

18.

Wu B, Becker JS. Bioimaging of metals in rat brain hippocampus by laser microdissection inductively coupled plasma mass spectrometry (LMD-ICP-MS) using high-efficiency laser ablation chambers. Int J Mass Spectrom 2012;323–324:34–40 (Elsevier) CrossRef

19.

Honda M, Nakamura M, Tateno M, Sakai A, Shimakami T, Shirasaki T, et al. Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C. J Hepatol 2010;53:817–826CrossRefPubMed

20.

Sansonno D, Tucci FA, De Re V, Lauletta G, Montrone M, Libra M, et al. HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology 2005;42:1019–1027CrossRefPubMed

21.

Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K, et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014;59:828–838CrossRefPubMed

22.

Chiu K-W, Nakano T, Chen K-D, Hu T-H, Lin C-C, Hsu L-W, et al. Identification of IL-28B genotype modification in hepatocytes after living donor liver transplantation by laser capture microdissection and pyrosequencing analysis. Biomed Res Int 2018;2018:1–8

23.

Munshaw S, Hwang HS, Torbenson M, Quinn J, Hansen KD, Astemborski J, et al. Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users. Hepatology 2012;56:544–554CrossRefPubMedPubMedCentral

24.

Wang H, Gao Y, Jin X, Xiao J. Expression of contactin associated protein-like 2 in a subset of hepatic progenitor cell compartment identified by gene expression profiling in hepatitis B virus-positive cirrhosis. Liver Int 2010;30:126–138CrossRefPubMed

25.

Deng H, Gao Y-B, Wang H-F, Jin X-L, Xiao J-C. Expression of deleted in malignant brain tumours 1 (DMBT1) relates to the proliferation and malignant transformation of hepatic progenitor cells in hepatitis B virus-related liver diseases. Histopathology 2012;60:249–260CrossRefPubMed

26.

Mishiro T, Hamamoto S, Furuta K, Ishimura N, Rumi MAK, Miyake T, et al. Quantitative measurement of hepatitis B virus DNA in different areas of hepatic lobules in patients with chronic hepatitis B. J Med Virol 2006;78:37–43CrossRefPubMed

27.

Tu T, Mason WS, Clouston AD, Shackel NA, McCaughan GW, Yeh MM, et al. Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J Viral Hepat 2015;22:737–753CrossRefPubMed

28.

Xu W, Wang N-R, Wang H-F, Feng Q, Deng J, Gong Z-Q, et al. Analysis of epithelial-mesenchymal transition markers in the histogenesis of hepatic progenitor cell in HBV-related liver diseases. Diagn Pathol 2016;11:136CrossRefPubMedPubMedCentral

29.

McDaniel K, Huang L, Sato K, Wu N, Annable T, Zhou T, et al. The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury. J Biol Chem 2017;292:11336–11347CrossRefPubMedPubMedCentral

30.

Ceulemans A, Verhulst S, Van Haele M, Govaere O, Ventura J-J, van Grunsven LA, et al. RNA-sequencing-based comparative analysis of human hepatic progenitor cells and their niche from alcoholic steatohepatitis livers. Cell Death Dis 2017;8:e3164CrossRefPubMedPubMedCentral

31.

Wu N, McDaniel K, Zhou T, Ramos-Lorenzo S, Wu C, Huang L, et al. Knockout of microRNA-21 attenuates alcoholic hepatitis through VHL/NF-κB signaling pathway in hepatic stellate cells. Am J Physiol Liver Physiol 2018;315(3):G385–G398. https://doi.org/10.1152/ajpgi.00111.2018 CrossRef

32.

Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 2017;66:1321–1328CrossRefPubMed

33.

Baba N, Kobashi H, Yamamoto K, Terada R, Suzuki T, Hakoda T, et al. Gene expression profiling in biliary epithelial cells of primary biliary cirrhosis using laser capture microdissection and cDNA microarray. Transl Res 2006;148:103–113CrossRefPubMed

34.

Gehring S, Dickson EM, San Martin ME, van Rooijen N, Papa EF, Harty MW, et al. Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology 2006;130:810–822CrossRefPubMed

35.

McDaniel K, Meng F, Wu N, Sato K, Venter J, Bernuzzi F, et al. Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡. Hepatology 2017;65:544–559 (NIH Public Access) CrossRefPubMed

36.

Katsumi T, Ninomiya M, Nishina T, Mizuno K, Tomita K, Haga H, et al. MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis. Lab Investig 2016;96:1165–1177CrossRefPubMed

37.

Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Borght SV, Gaudio E, et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010;59:247–257CrossRefPubMed

38.

Adam AC, Faudou V, Paschen SA, Adam OM, Kahl P, Drebber U, et al. Hepatocarcinogenesis in non-cirrhotic liver is associated with a reduced number of clonal hepatocellular patches in non-tumorous liver parenchyma. J Pathol 2012;228:333–340CrossRefPubMed

39.

Melis M, Diaz G, Kleiner DE, Zamboni F, Kabat J, Lai J, et al. Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus—associated hepatocellular carcinoma. J Transl Med 2014;12:230CrossRefPubMedPubMedCentral

40.

Yang Y, Lin X, Lu X, Luo G, Zeng T, Tang J, et al. Interferon-microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis. Gut 2016;65:1186–1201CrossRefPubMedPubMedCentral

41.

Michael AOA, Ahsan N, Zabala V, Francois-Vaughan H, Post S, Brilliant KE, et al. Proteomic analysis of laser capture microdissected focal lesions in a rat model of progenitor marker-positive hepatocellular carcinoma. Oncotarget 2017;8:26041–26056CrossRefPubMedCentral

42.

Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090–1098CrossRefPubMed

43.

Chen L, Yan H-X, Yang W, Hu L, Yu L-X, Liu Q, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009;50:358–369 (Elsevier) CrossRefPubMed

44.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142(1021–1031):e15 (NIH Public Access)

45.

Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013;119:1669–1674CrossRefPubMed

46.

Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013;58:1992–2000CrossRefPubMed

47.

Asukai K, Kawamoto K, Eguchi H, Konno M, Asai A, Iwagami Y, et al. Micro-RNA-130a-3p regulates gemcitabine resistance via PPARG in cholangiocarcinoma. Ann Surg Oncol 2017;24:2344–2352CrossRefPubMed

48.

Iida M, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S, et al. Overexpression of miR-221 and miR-222 in the cancer stroma is associated with malignant potential in colorectal cancer. Oncol Rep 2018;40:1621–1631PubMed

49.

Iino I, Kikuchi H, Miyazaki S, Hiramatsu Y, Ohta M, Kamiya K, et al. Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis. Cancer Sci 2013;104:624–630CrossRefPubMed

50.

Murakami T, Kikuchi H, Ishimatsu H, Iino I, Hirotsu A, Matsumoto T, et al. Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis. Br J Cancer 2017;117(9):1360CrossRefPubMedPubMedCentral

51.

Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67–108CrossRefPubMed

Title: Laser capture microdissection: techniques and applications in liver diseases
Authors: Beatriz Aguilar-Bravo
Pau Sancho-Bru
Publication date: 01-03-2019
Publisher: Springer India
Keyword: Laser
Published in: Hepatology International / Issue 2/2019
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-018-9917-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Laser capture microdissection: techniques and applications in liver diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting

Goals and targets for personalized therapy for HCC

Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms

Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India

The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan

Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page